Cargando…

LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma

BACKGROUND: Lymphocyte activating 3 (LAG3, LAG-3, CD223) is a promising target for immune checkpoint inhibition in clear cell renal cell carcinoma (KIRC). The aim of this study was to investigate the epigenetic regulation of LAG3 in KIRC by methylation. METHODS: We correlated quantitative LAG3 methy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klümper, Niklas, Ralser, Damian J, Bawden, Emma Grace, Landsberg, Jenny, Zarbl, Romina, Kristiansen, Glen, Toma, Marieta, Ritter, Manuel, Hölzel, Michael, Ellinger, Jörg, Dietrich, Dimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174079/ https://www.ncbi.nlm.nih.gov/pubmed/32234847 http://dx.doi.org/10.1136/jitc-2020-000552

Ejemplares similares

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2021)

Stromal LAG-3(+) cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture
por: Zeng, Han, et al.
Publicado: (2020)

Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
por: Fröhlich, Anne, et al.
Publicado: (2020)

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
por: Klümper, Niklas, et al.
Publicado: (2022)

Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity
por: Burnell, Stephanie E A, et al.
Publicado: (2021)

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures
por: Gestermann, Nicolas, et al.
Publicado: (2020)

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
por: Schöffski, Patrick, et al.
Publicado: (2022)

Clinical Significance of Soluble LAG-3 (sLAG-3) in Patients With Cervical Cancer Determined via Enzyme-Linked Immunosorbent Assay With Monoclonal Antibodies
por: Li, Yang, et al.
Publicado: (2023)

T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 – MHCII blocking capacity
por: Cemerski, Saso, et al.
Publicado: (2015)

FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III
por: Jiang, Minlin, et al.
Publicado: (2021)

Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients
por: Xiong, Ying, et al.
Publicado: (2020)

Understanding LAG-3 Signaling
por: Chocarro, Luisa, et al.
Publicado: (2021)

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
por: Hwang, Michael, et al.
Publicado: (2022)

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Reschke, Robin, et al.
Publicado: (2021)

LAG3’s Enigmatic Mechanism of Action
por: Graydon, Colin G., et al.
Publicado: (2021)

Overcoming the LAG3 phase problem
por: Petersen, Jan, et al.
Publicado: (2022)

T-cell tolerant fraction as a predictor of immune-related adverse events
por: Ostmeyer, Jared, et al.
Publicado: (2023)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
por: Sise, Meghan E, et al.
Publicado: (2023)

Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
por: Xu, Wenhao, et al.
Publicado: (2023)

B7 score and T cell infiltration stratify immune status in prostate cancer
por: Zhou, Qianghua, et al.
Publicado: (2021)

Prognostic significance of myeloid immune cells and their spatial distribution in the colorectal cancer microenvironment
por: Väyrynen, Juha P, et al.
Publicado: (2021)

Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
por: Shi, An-Ping, et al.
Publicado: (2022)

Downstream neighbor of SON (DONSON) is associated with unfavorable survival across diverse cancers with oncogenic properties in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2020)

Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases
por: Lu, Benjamin Y, et al.
Publicado: (2021)

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
por: Borchmann, Peter, et al.
Publicado: (2022)

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
por: Timmerman, John, et al.
Publicado: (2022)

m(6)A modification patterns and tumor immune landscape in clear cell renal carcinoma
por: Zhong, Jiehui, et al.
Publicado: (2021)

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
por: Brown, Landon C, et al.
Publicado: (2022)

Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment
por: Kim, Hyunsu, et al.
Publicado: (2023)

Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma
por: Yao, Yao, et al.
Publicado: (2020)

Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management
por: Marté, Jennifer L, et al.
Publicado: (2020)

Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity
por: Sorin, Mark, et al.
Publicado: (2023)

Discovery of a glucocorticoid receptor (GR) activity signature correlates with immune cell infiltration in adrenocortical carcinoma
por: Wu, Kan, et al.
Publicado: (2023)

LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice
por: Mulholland, Megan, et al.
Publicado: (2022)

Diminished LAG3(+) B cells correlate with exacerbated rheumatoid arthritis
por: Hu, Suiyuan, et al.
Publicado: (2023)

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
por: Schina, Aimilia, et al.
Publicado: (2023)

LAG-3 expression in the inflammatory microenvironment of glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

Clinical landscape of LAG-3-targeted therapy
por: Chocarro, L., et al.
Publicado: (2022)

LAG3 in gastric cancer: it’s complicated
por: Ulase, Dita, et al.
Publicado: (2023)

Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
por: Weppler, Alison M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vt0umamdl4au72imrdkib23ego